Age (years), mean ± SD |
|
46.2 ± 16.2 |
Sex, n (%) |
Female |
6 (28.6) |
|
Male |
15 (71.4) |
Length of hospital stay (days), median (IQR) |
|
31
(25–46) |
Indications for tigecycline, n (%) |
Pneumonia |
6
(28.6) |
|
Agranulocytosis |
5 (23.8) |
|
Multiple organ failure |
3 (14.3) |
|
Sepsis |
2 (9.5) |
|
Major surgery-related infection |
2 (9.5) |
|
Mixed infections in more than one part |
1 (4.8) |
|
Intra-abdominal infection |
1 (4.8) |
|
Septicemia |
1 (4.8) |
Loading dose of tigecycline, n (%) |
100 mg |
11 (52.4) |
|
400 mg |
1 (4.8) |
|
None |
9 (42.9) |
Maintenance dose of tigecycline, n (%) |
100 mg q12h |
2
(9.5) |
|
50 mg q12h |
16 (76.2) |
|
100 mg q12h and 50 mg q12h |
3 (14.3) |
Duration of tigecycline use (days), median (IQR) |
|
11
(5–13) |
Total dose (mg), median (IQR) |
|
1200 (850–1650) |
Time from tigecycline use to symptom onset (days), mean ± SD |
|
7.2 ±
4.2 |
Presenting symptoms, n (%) |
Abdominal pain/discomfort/nausea/vomiting |
16 (76.2) |
|
None |
5 (23.8) |
AP severity, n (%) |
Mild |
21 (100) |
Modified CT severity score, median (IQR) |
|
2 (0–2) |
Amylase after tigecycline use (U/L), mean ± SD |
|
135.8 ±
57.8 |
Lipase after tigecycline use (U/L), mean ± SD |
|
347.1 ±
221.8 |
Time to symptom relief (days), mean ± SD |
|
3.6 ± 1.9 |
Time to enzyme recovery (days), mean ± SD |
|
7.1 ± 3.6 |
Naranjo score, mean ± SD |
|
7.2 ± 1.5 |